SCHEMBL22904375

SCHEMBL22904375

O=C1Cc2cccc(Oc3cccc4ccncc34)c2C(=O)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 7/20 0.44
BRD4 O60885 1/20 0.36
CASP3 P42574 1/20 0.35
CASP7 P55210 1/20 0.35
CASP9 P55211 1/20 0.35
CASP6 P55212 1/20 0.35
CASP8 Q14790 1/20 0.35
MAP3K14 Q99558 1/20 0.35
PTK2 Q05397 2/20 0.34
TNF P01375 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
LDLR P01130 1/20 0.33
PDGFRB P09619 1/20 0.33
KIT P10721 1/20 0.33
SRC P12931 1/20 0.33
PCSK9 Q8NBP7 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNT2 O60583 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22904285 0.85 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904369 0.79 TDP2 (0.50) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904103 0.73 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904128 0.73 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904252 0.73 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904129 0.73 AHR (0.54) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904393 0.73 TDP2 (0.51) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904148 0.73 TDP2 (0.48) TDP2CASP3CASP7CASP9CASP6
SCHEMBL22904525 0.72 TDP2 (0.54) TDP2BRD4CASP3CASP7CASP9
SCHEMBL29794338 0.70 TDP2 (0.48) TDP2CASP3CASP7CASP9CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011631-A1 FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-01-21 WO disclosed
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES AUSPEX PHARMACEUTICALS, INC. 2016-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160331734-A1 SUBSTITUTED N-ARYL PYRIDINONES COL1A1, COL2A1, COLGALT1 TDP2 3657/4885BRD4 696/4885CASP3 2951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.